Vistagen reports narrower net loss of $6.3M in fiscal Q3; fasedienol trials on track

Vistagen Therapeutics, Inc.

2025-Q3 EPS reported -$1.27 vs consensus -$0.49 ▼ miss (-161.6%)

Net loss $6.3M vs $9.8M YoY; cash $126.6M at Dec 31, 2023.
R&D expense $4.5M, down from $6.9M on lower clinical costs.
G&A expense $3.8M, up from $3.1M on compensation.
PALISADE-3 fasedienol trial for SAD initiation expected 1H 2024; PALISADE-4 in 2H 2024.
Preparations underway for itruvone Phase 2B in MDD and PH80 Phase 2B in vasomotor symptoms.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vistagen Therapeutics, Inc. reported fiscal year 2024 third quarter ended December 31, 2023 results: net income $6.3 million.

Period: fiscal year 2024 third quarter ended December 31, 2023
Net income: $6.3 million
Result: reported results

Exact text from the filing

Net loss: Net loss was $6.3 million and $9.8 million for the three months ended December 31, 2023, and 2022, respectively.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Vistagen Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-003924

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.